Concord Drugs MD, chairman, board of directors and AGM
BSE: 538965Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹69.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90 Cr3,001st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 43.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 5.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 7.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.28
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,703
Concord Drugs board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorS.Nagi Reddy
- Company Secretary and Compliance OfficerNamratha nagla
6 directors3 independent3 executive
- S.Nagi Reddy · Chairperson and managing directorExecutive · joined Apr 2003 · reappointed Sep 2025 · 1 listed board
- S.Koni ReddyExecutive · joined Jun 2011 · reappointed Sep 2025 · 1 listed board
- S. Nagavenkata HareeshIndependent · joined Feb 2021 · reappointed Feb 2021 · 64 months as independent · 1 listed board · 1 as independent · 3 committee seats
- S.Manoj Kumar ReddyExecutive · joined Aug 2021 · reappointed Sep 2025 · 1 listed board
- Kasu SumeelaIndependent · joined Jun 2022 · reappointed Jun 2022 · 46 months as independent · 1 listed board · 1 as independent · 3 committee seats, 3 as chair
- Satyam Reddy GopidiIndependent · joined Sep 2025 · 9 months as independent · 1 listed board · 1 as independent · 3 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- K. Ramachandra Reddy, left 14 Feb 2026: Tenure Completion
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 27 May 20266 of 6 present3 independent · 101 days in between
- 14 Feb 20266 of 6 present3 independent
Audit Committee
Chair Kasu Sumeela
S. Nagavenkata Hareesh, Satyam Reddy Gopidi
- 27 May 20263 of 3 present3 independent · 1 day in between
- 14 Feb 20263 of 3 present3 independent
Nomination and remuneration committee
Chair Kasu Sumeela
S. Nagavenkata Hareesh, Satyam Reddy Gopidi
- 14 Feb 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair Kasu Sumeela
S. Nagavenkata Hareesh, Satyam Reddy Gopidi
- 25 May 20263 of 3 present3 independent · 60 days in between
- 25 Mar 20263 of 3 present3 independent · 38 days in between
- 14 Feb 20263 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- PUNDARIKASHYAM AND ASSOCIATESPeer-review certificate valid to Oct 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Concord Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Concord Drugs share news and announcements
Annual general meeting, 30 Sep 2026
4,482 shareholders on the register on 23 Sep 2026; present: 3 promoters and 60 others; votes counted by Srikant Kumar Puthi / PSK and Associates.The company's voting result (opens in a new tab)
- TO RECEIVE, CONSIDER AND ADOPT THE AUDITED STANDALONE AND CONSOLIDATED FINANCIAL STATEMENTSOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- TO APPOINT A DIRECTOR IN PLACE OF MR. S. NAGI REDDY, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENTOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- RE-APPOINTMENT OF STATUTORY AUDITORS FOR A SECOND TERM OF FIVE CONSECUTIVE YEARSOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- TO APPROVE THE RELATED PARTY TRANSACTIONS TO BE ENTERED FOR THE FINANCIALYEAR 2026-27Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- RATIFICATION OF PAYMENT OF REMUNERATION OF M/S. KJU & ASSOCIATES, COST AUDITORS OF THE COMPANY FOR THE FINANCIAL YEAR 2026-2027Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- RE-APPOINTMENT OF MR. S. NAGAVENKATA HAREESH KUMAR SOLLETI (DIN: 09066790) AS AN INDEPENDENT DIRECTORSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
- RE-APPOINTMENT OF MS. SUMEELA KASU (DIN: 09571540) AS AN INDEPENDENT DIRECTORSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 48.41% · promoters 100.00% · institutions 0.00% · other public 6.06%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states is more than ten times everything the company owns, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesNov 2025 | – | – | – | No |